Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Sepracor Plans Alvesco, Omnaris Drug Launches Following Acquisition From Nycomed

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Sepracor’s 1,600-person sales force will promote the asthma and allergic rhinitis treatments.

You may also be interested in...



Sepracor Reports Promising Phase III Data For Epilepsy Compound

Late 2008/early 2009 NDA filing is targeted for eslicarbazepine as adjunct therapy for epileptic seizure control.

Sepracor Reports Promising Phase III Data For Epilepsy Compound

Late 2008/early 2009 NDA filing is targeted for eslicarbazepine as adjunct therapy for epileptic seizure control.

Sepracor Will Ramp Up Sales Force To Launch NycoMed Drugs

Company will add 200 reps this year to promote Omnaris and Alvesco, as well as existing products like Lunesta.

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing

Global Pharma Guidance Tracker – March 2024

See All
UsernamePublicRestriction

Register

PS066807

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By